Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma

Table 2 TSHR mRNA levels of the study groups

Group	TSHR mRNA median (range)^a			TSHR mRNA >2.0^a	Serum Tg > 0.3^b
Group	Total	TgAb-ve	TgAb + ve	TSHR mRNA >2.0^a	Serum Tg > 0.3^b
Control subject	2.19 (1.30–2.99)	2.19 (1.30–2.99)	-	-	-
Control subject	n = 27	n = 27	-	-	-
No evidence of disease	2.32 (1.44–3.94)	2.32 (1.44–3.94)	-	57.1 %	18.4 %
No evidence of disease	n = 49	n = 49	-	57.1 %	18.4 %
Thyroid remnants	3.21 (2.22-3.88)	3.05 (1.71–3.63)	4.24 (3.39–5.08)	78.6 %	7.1 %
Thyroid remnants	n = 14	n = 12	n = 2	78.6 %	7.1 %
Biochemical persistent disease	2.72 (1.51–3.98)	2.42 (1.21–3.98)	3.59 ± 2.37	64.3 %	53.6 %
Biochemical persistent disease	n = 28	n = 20	n = 8	64.3 %	53.6 %
Structural persistent disease	2.75 (1.37–3.83)	2.22 (1.13–3.28)	3.47 (2.97–9.53)^c	62.3 %	79.7 %
Structural persistent disease	n = 69	n = 52	n = 17	62.3 %	79.7 %
Locoregional disease	2.56 (1.19–5.03)	2.00 (1.03–4.93)	3.01 (1.89–8.16)	60.0 %	80.0 %
Locoregional disease	n = 25	n = 19	n = 6	60.0 %	80.0 %
Distant metastasis	2.92 (1.40–3.49)	2.24 (1.17–3.19)	5.55 (3.28–12.52)^c	63.6 %	79.5 %
Distant metastasis	n = 44	n = 33	n = 11	63.6 %	79.5 %

ISSN: 1756-6614